Chardan Capital Cuts Cognition Therapeutics (NASDAQ:CGTX) Price Target to $8.00

Cognition Therapeutics (NASDAQ:CGTX) had its price objective trimmed by Chardan Capital from $11.00 to $8.00 in a research report report published on Friday,Benzinga reports. The brokerage currently has a buy rating on the stock.

Several other research analysts have also recently weighed in on the stock. B. Riley upgraded shares of Cognition Therapeutics from a “neutral” rating to a “buy” rating and upped their price objective for the stock from $1.00 to $1.50 in a research report on Thursday, December 19th. HC Wainwright increased their price target on shares of Cognition Therapeutics from $5.00 to $6.00 and gave the stock a “buy” rating in a report on Thursday, December 19th. Finally, Brookline Capital Management raised shares of Cognition Therapeutics to a “strong-buy” rating in a report on Monday, January 27th. One equities research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $7.70.

Cognition Therapeutics Price Performance

Shares of NASDAQ:CGTX opened at $0.45 on Friday. The company has a market cap of $18.90 million, a price-to-earnings ratio of -0.47 and a beta of 1.03. Cognition Therapeutics has a one year low of $0.34 and a one year high of $2.95. The firm has a fifty day moving average price of $0.58 and a two-hundred day moving average price of $0.55.

Cognition Therapeutics (NASDAQ:CGTX) last posted its earnings results on Thursday, March 20th. The company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.16) by ($0.01). During the same period last year, the firm posted ($0.27) earnings per share. Equities research analysts expect that Cognition Therapeutics will post -0.8 EPS for the current fiscal year.

Institutional Investors Weigh In On Cognition Therapeutics

Institutional investors have recently made changes to their positions in the business. Virtu Financial LLC raised its position in Cognition Therapeutics by 40.1% in the 4th quarter. Virtu Financial LLC now owns 80,180 shares of the company’s stock worth $56,000 after purchasing an additional 22,949 shares during the period. Geode Capital Management LLC grew its stake in shares of Cognition Therapeutics by 8.9% during the fourth quarter. Geode Capital Management LLC now owns 352,348 shares of the company’s stock valued at $247,000 after buying an additional 28,705 shares during the last quarter. SG Americas Securities LLC purchased a new position in shares of Cognition Therapeutics in the fourth quarter worth about $26,000. Two Sigma Investments LP increased its holdings in shares of Cognition Therapeutics by 372.2% in the fourth quarter. Two Sigma Investments LP now owns 53,691 shares of the company’s stock worth $38,000 after buying an additional 42,321 shares during the period. Finally, Sigma Planning Corp boosted its holdings in Cognition Therapeutics by 211.6% during the 4th quarter. Sigma Planning Corp now owns 614,490 shares of the company’s stock valued at $431,000 after acquiring an additional 417,300 shares during the period. Hedge funds and other institutional investors own 43.35% of the company’s stock.

About Cognition Therapeutics

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.